Effects of Isoflavone Supplementation on the Response to Medroxyprogesterone in Premenopausal Women with Nonatypical Endometrial Hyperplasia: A Randomized, Double-Blind, Placebo-Controlled Trial

Objective. The purpose of this study was to evaluate the impact of isoflavone supplementation compared with placebo on endometrial histology and serum estradiol levels in premenopausal women with nonatypical endometrial hyperplasia. Materials and Methods. The present double-blindplacebo-controlled c...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:International journal of clinical practice (Esher) Ročník 2022; číslo 1; s. 1263544
Hlavní autoři: Vahedpour, Zahra, Boroumand, Homa, Tabatabaee Anaraki, Shirin, Tabasi, Zohre, Motedayyen, Hossein, Akbari, Hossein, Raygan, Fariba, Ostadmohammadi, Vahidreza
Médium: Journal Article
Jazyk:angličtina
Vydáno: India Hindawi 2022
John Wiley & Sons, Inc
Wiley
Témata:
17β-Estradiol
Acetic acid
Adult
Analysis of covariance
Biopsy
Blood pressure
Body mass index
Cancer therapies
Chi-square test
Clinical trials
Diabetes
Dietary Supplements
Double-Blind Method
Drug-Related Side Effects and Adverse Reactions
Endometrial cancer
Endometrial Hyperplasia - chemically induced
Endometrial Hyperplasia - drug therapy
Endometrial Hyperplasia - epidemiology
Endometrium
Estradiol - adverse effects
Estrogens
Female
Gynecology
Histology
Humans
Hyperplasia
Iran
Isoflavones
Isoflavones - adverse effects
Medroxyprogesterone
Medroxyprogesterone acetate
Middle Aged
Pharmaceutical industry
Placebos
Sample size
Side effects
Iran
ISSN:1368-5031, 1742-1241, 1742-1241
On-line přístup:Získat plný text
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:Objective. The purpose of this study was to evaluate the impact of isoflavone supplementation compared with placebo on endometrial histology and serum estradiol levels in premenopausal women with nonatypical endometrial hyperplasia. Materials and Methods. The present double-blindplacebo-controlled clinical trial was conducted on 100 women with nonatypical endometrial hyperplasia in the age range of 30 to 45 years. Participants were randomly assigned to receive 50 mg of isoflavone (n = 50) or placebos (n = 50) daily for three months. Both groups received the standard treatment of nonatypical endometrial hyperplasia. Endometrial biopsy and blood samples were taken at the baseline and three months after the intervention. The incidence of drug side effects was assessed as well. Results. After three months, 88.4% of isoflavone-administered subjects had a significant histological improvement compared to 68.9% subjects in the placebo group (P=0.02). There were no significant differences between the two groups in the changes of serum estradiol levels and the incidence of drug side effects. Conclusion. The findings of the present study demonstrated that the coadministration of 50 mg of isoflavones and medroxyprogesterone acetate increases the treatment efficacy in women with nonatypical endometrial hyperplasia. Clinical Trial Registration. This trial was registered on the Iranian website for clinical trial registration (https://www.irct.ir/trial/53553).
Bibliografie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Article-2
ObjectType-Undefined-1
ObjectType-Feature-3
content type line 23
ISSN:1368-5031
1742-1241
1742-1241
DOI:10.1155/2022/1263544